We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cooper Companies (COO) Misses on Q2 Earnings and Revenues
Read MoreHide Full Article
The Cooper Companies, Inc. (COO - Free Report) reported second-quarter fiscal 2020 adjusted earnings per share of $1.51, which lagged the Zacks Consensus Estimate of $2.13 by 29.1%. The bottom line also deteriorated 48.6% on a year-over-year basis.
Revenues of this Zacks Rank #4 (Sell) company came in at $524.9 million, missing the Zacks Consensus Estimate by 10%. Also, on a year-over-year basis, the top line declined 19.8%.
Q2 Segment Details
CooperVision (CVI)
This segment’s revenues totaled $402.2 million, down 15% at constant currency (cc) and 17% on a reported basis.
Per management, the segment saw a noticeable decline in revenues from Single-use sphere lenses (29% of CVI), reflecting a decrease of 13% at cc. Single-use sphere lenses revenues totaled $116.1 million.
Toric (33% of CVI) revenues totaled $133.6 million, down 13% at cc.
Multifocal (11% of CVI) generated revenues of $45.1 million, down 7% at cc.
Non single-use sphere (27% of CVI) revenues came in at $107.4 million, down 24% at cc and 25% from the year-ago quarter.
Geographically, the segment witnessed a deterioration in revenues in the Americas (38% of CVI), down 22% at cc and 23% year over year to $149.6 million.
EMEA revenues (38% of CVI) totaled $154.1 million, down 11% at cc and 15% from the prior-year quarter.
Asia Pacific sales (24% of CVI) declined 10% at cc and 10% year over year to $98.5 million.
The Cooper Companies, Inc. Price, Consensus and EPS Surprise
This segment posted revenues of $122.7 million, down 27% at cc and 28% on a year-over-year basis.
Sub-segment Office and Surgical products (57% of CSI) accounted for $69.6 million revenues, down 34% at cc and on a year-over-year basis.
Fertility (43% of CSI) revenues were $53.1 million, down 17% year over year and 15% at cc.
Margin Analysis
In the fiscal second quarter, gross profit was $323.5 million, down 25.2% year over year. Gross margin was 61.6% of net revenues, down 450 basis points (bps) year over year.
Operating income in the quarter totaled $28.6 million, which plunged 80.5% year over year. Operating margin was 5.4%, down 1710 bps from the prior-year quarter.
Fiscal 2020 Guidance
Given uncertainty surrounding the COVID-19 pandemic and its impact on near-term financial results, the company is no longer issuing fiscal 2020 outlook.
Wrapping Up
Cooper Companies exited the fiscal second quarter on a weak note. The company saw weak performance across core CVI and CSI units. Also, the contraction in margins raises a concern. Moreover, the company’s top line declined on a year-over-year basis in the quarter. Non single-use sphere sales were soft, and CVI revenues declined in the Americas, EMEA as well as APAC.
Nonetheless, management remains optimistic about the Clarity, MyDay and Biofinity suite of products. The company’s portfolio of daily silicone hydrogel lenses makes it one of the leaders in the soft contact lens market.
Key Picks
Some better-ranked stocks in the broader medical space include Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million surpassed the consensus mark by 14.6%. The company carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly reported first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Cooper Companies (COO) Misses on Q2 Earnings and Revenues
The Cooper Companies, Inc. (COO - Free Report) reported second-quarter fiscal 2020 adjusted earnings per share of $1.51, which lagged the Zacks Consensus Estimate of $2.13 by 29.1%. The bottom line also deteriorated 48.6% on a year-over-year basis.
Revenues of this Zacks Rank #4 (Sell) company came in at $524.9 million, missing the Zacks Consensus Estimate by 10%. Also, on a year-over-year basis, the top line declined 19.8%.
Q2 Segment Details
CooperVision (CVI)
This segment’s revenues totaled $402.2 million, down 15% at constant currency (cc) and 17% on a reported basis.
Per management, the segment saw a noticeable decline in revenues from Single-use sphere lenses (29% of CVI), reflecting a decrease of 13% at cc. Single-use sphere lenses revenues totaled $116.1 million.
Toric (33% of CVI) revenues totaled $133.6 million, down 13% at cc.
Multifocal (11% of CVI) generated revenues of $45.1 million, down 7% at cc.
Non single-use sphere (27% of CVI) revenues came in at $107.4 million, down 24% at cc and 25% from the year-ago quarter.
Geographically, the segment witnessed a deterioration in revenues in the Americas (38% of CVI), down 22% at cc and 23% year over year to $149.6 million.
EMEA revenues (38% of CVI) totaled $154.1 million, down 11% at cc and 15% from the prior-year quarter.
Asia Pacific sales (24% of CVI) declined 10% at cc and 10% year over year to $98.5 million.
The Cooper Companies, Inc. Price, Consensus and EPS Surprise
The Cooper Companies, Inc. price-consensus-eps-surprise-chart | The Cooper Companies, Inc. Quote
CooperSurgical (CSI)
This segment posted revenues of $122.7 million, down 27% at cc and 28% on a year-over-year basis.
Sub-segment Office and Surgical products (57% of CSI) accounted for $69.6 million revenues, down 34% at cc and on a year-over-year basis.
Fertility (43% of CSI) revenues were $53.1 million, down 17% year over year and 15% at cc.
Margin Analysis
In the fiscal second quarter, gross profit was $323.5 million, down 25.2% year over year. Gross margin was 61.6% of net revenues, down 450 basis points (bps) year over year.
Operating income in the quarter totaled $28.6 million, which plunged 80.5% year over year. Operating margin was 5.4%, down 1710 bps from the prior-year quarter.
Fiscal 2020 Guidance
Given uncertainty surrounding the COVID-19 pandemic and its impact on near-term financial results, the company is no longer issuing fiscal 2020 outlook.
Wrapping Up
Cooper Companies exited the fiscal second quarter on a weak note. The company saw weak performance across core CVI and CSI units. Also, the contraction in margins raises a concern. Moreover, the company’s top line declined on a year-over-year basis in the quarter. Non single-use sphere sales were soft, and CVI revenues declined in the Americas, EMEA as well as APAC.
Nonetheless, management remains optimistic about the Clarity, MyDay and Biofinity suite of products. The company’s portfolio of daily silicone hydrogel lenses makes it one of the leaders in the soft contact lens market.
Key Picks
Some better-ranked stocks in the broader medical space include Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million surpassed the consensus mark by 14.6%. The company carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly reported first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>